RxDoctor Payments Data

Pei-Chi Fu, MD

Family Medicine · Las Vegas, NVNPI 1053363473

Payments from drug & device makers

$2,055in general payments, 2019–2025

Across 101 payments — averaging $20.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$453
  • Pfizer$262
  • Boehringer Ingelheim$195
  • Lilly USA, LLC$191
  • Novo Nordisk$189
  • Incyte Corporation$124
  • plus $641 from 14 others

What the payments were for

  • Food & beverage$2,04099%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,055 in reported general payments places this provider in the 75th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$19,293
Medicare patients
67
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin68$91,404
OzempicSemaglutide37$57,155
EliquisApixaban41$50,834
MounjaroTirzepatide22$36,313
TrulicityDulaglutide11$29,679
Breztri AerosphereBudesonide/Glycopyr/Formoterol20$24,536
FarxigaDapagliflozin Propanediol11$18,945
JanuviaSitagliptin Phosphate12$18,480
XareltoRivaroxaban11$16,229
Lantus SolostarInsulin Glargine,hum.Rec.Anlog26$4,726
Albuterol Sulfate HfaAlbuterol Sulfate97$4,711
Novolin RInsulin Regular, Human14$3,558
Atorvastatin Calcium417$2,560
Losartan Potassium245$2,028
Levothyroxine Sodium207$1,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$195$91,40468 claims
Lilly USA, LLCMounjaro, Trulicity$191$65,99233 claims
Novo NordiskOzempic$189$57,15537 claims
PfizerEliquis$262$50,83441 claims
AstraZenecaBreztri Aerosphere, Farxiga$453$43,48231 claims
MerckJanuvia$57$18,48012 claims
Johnson & JohnsonXarelto$49$16,22911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 902 family medicine providers in Nevada.

Other family medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →